Literature DB >> 6330151

Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women.

M C Gelato, O H Pescovitz, F Cassorla, D L Loriaux, G R Merriam.   

Abstract

Human GRF-(1-44)-NH2 (GRF-44) was administered iv in graded doses of 0.01-10 micrograms/kg to 35 normal young adult men and 38 women. GRF-44 stimulated the release of GH in a dose-dependent fashion, although the individual responses varied widely. The ED50 values for this effect were 0.4 micrograms/kg in men and 0.2 micrograms/kg in women in the midfollicular phase of the menstrual cycle. Maximal responses in men and women were not significantly different, and a dose of 1 micrograms/kg was sufficient to produce a maximal response. There was, likewise, no difference between responses of women tested in the midfollicular and midluteal phases of the cycle. There were no changes in PRL, LH, FSH, TSH, ACTH, beta-endorphin, or cortisol at doses up to 1 microgram/kg; at 10 micrograms/kg, PRL increased by an average of 7.6 ng/ml in the women. Side effects occurred in approximately 20% of both men and women at 1 microgram/kg and in nearly all subjects given 10 micrograms/kg; these consisted primarily of flushing and a sense of warmth. Thus, a dose of 1 microgram/kg GRF-44 is safe and effective, and would appear to be a reasonable choice for use in studying GH responses in normal subjects of other ages and in patients with disorders of GH secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330151     DOI: 10.1210/jcem-59-2-197

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans.

Authors:  E Arvat; L Di Vito; F Broglio; M Papotti; G Muccioli; C Dieguez; F F Casanueva; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

Review 2.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Synthetic human growth hormone releasing factor (h-GRF-I-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men.

Authors:  J P Boissel; R Cohen; S Biot-Laporte; B Claustrat; H Renard; M Olivier; G Sassolas
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Growth hormone-releasing hormone: a clinical perspective.

Authors:  R Khardori; P S Menon
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

Review 5.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256

6.  IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

Authors:  M H Borges; A C Pinto; F B DiNinno; C Camacho-Hübner; A Grossman; C E Kater; A M Lengyel
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

7.  Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses.

Authors:  P Girard; R Cohen; G Sassolas; C Harthe; P Cabrera; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

9.  Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth.

Authors:  A Wieck; R Kumar; A D Hirst; M N Marks; I C Campbell; S A Checkley
Journal:  BMJ       Date:  1991-09-14

10.  Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency.

Authors:  M B Ranke; M Gruhler; R Rosskamp; G Brügmann; A Attanasio; W F Blum; J R Bierich
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.